Notably, mutations in BRCA1/2 have been implicated in the pathogenesis of many cancers, such as breast and ovarian cancers17, and several PARP inhibitors have been approved by the US Food and Drug Administration (FDA) for BRCA1/2-mutant ovarian and breast cancers3,4. Here, PARP1 is linked to cancer.